CAT Allergen Conjugates and Uses Thereof

Abstract

The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.

1 . A composition comprising:
 (a) a core particle with at least one first attachment site, wherein said core particle is a virus-like particle (VLP) of an RNA bacteriophage,   (b) at least one antigen with at least one second attachment site,
 wherein said at least one antigen is a Fel d1 protein or a Fel d1 protein, wherein said Fel d1 protein is a fusion protein comprising chain 1 of Fel d1 and chain 2 of Fel d1, wherein said chain 1 of Fel d1 is fused via its C-terminus to the N-terminus of said chain 2 of Fel d1 via a spacer consisting of an amino acid sequence having 10-20 amino acid residues, wherein said fusion protein is not expressed in baculovirus expression system, and wherein (a) and (b) are covalently linked through said at least one first and said at least one second attachment site. 
   
     
     
         2 - 7 . (canceled) 
     
     
         8 . The composition of  claim 1 , wherein said chain 1 of Fel d 1 comprises a sequence of SEQ ID NO:22 or a homologue sequence thereof, wherein said homologue sequence has an identity to SEQ ID NO:22 of greater than 95%. 
     
     
         9 . The composition of  claim 1 , wherein said chain 2 of Fel d 1 comprises a sequence of SEQ ID NO:23, SEQ ID NO:25 or SEQ ID NO:26, or a homologue sequence thereof, wherein said homologue sequence has an identity to SEQ ID NO:23, SEQ ID NO:25 or SEQ ID NO:26 of greater than 95%. 
     
     
         10 - 12 . (canceled) 
     
     
         13 . The composition of  claim 1 , wherein said first attachment site comprises an amino group of a lysine. 
     
     
         14 . The composition of  claim 1 , wherein said second attachment site comprises a sulfhydryl group of a cysteine. 
     
     
         15 . (canceled) 
     
     
         16 . The composition of  claim 1  further comprising a linker, wherein said linker is fused to the C-terminus of said Fel d1 protein, and wherein said linker comprises said second attachment site and comprises a cysteine residue. 
     
     
         17 . (canceled) 
     
     
         18 . The composition of  claim 1  further comprising at least one adjuvant. 
     
     
         19 . A pharmaceutical composition comprising:
 (a) the composition of  claim 1 ; and   (b) an acceptable pharmaceutical carrier.   
     
     
         20 . A method of producing the composition of  claim 1  comprising:
 (a) providing a core particle with at least one first attachment site, wherein said core particle is a virus-like particle (VLP) of an RNA-bacteriophage; 
 (b) providing at least one antigen with at least one second attachment site, wherein said antigen is a Fel d1 protein, wherein said Fel d1 protein is a fusion protein comprising chain 1 of Fel d1 and chain 2 of Fel d1, wherein said chain 1 of Fel d1 is fused via its C-terminus to the N-terminus of said chain 2 of Fel d1 via a spacer consisting of an amino acid sequence having 10-20 amino acid residues, wherein said fusion protein is not expressed in baculovirus expression system, and 
 (c) linking said core particle and said at least one antigen to produce said composition, wherein said at least one antigen and said core particle are linked through said at least one first and said at least one second attachment sites. 
 
     
     
         21 . (canceled) 
     
     
         22 . A method of treating cat allergy comprising administering the composition of  claim 1  to a human or to a non-human mammal. 
     
     
         23 - 30 . (canceled) 
     
     
         31 . The composition of  claim 1 , wherein said RNA-bacteriophage is AP205. 
     
     
         32 . The composition of  claim 1 , wherein said fusion protein comprises the amino acid sequence as set forth in SEQ ID NO:57. 
     
     
         33 . The composition of  claim 1 , wherein said core particle is a VLP of RNA-bacteriophage Qβ. 
     
     
         34 . The composition of  claim 1 , wherein said first attachment site is linked to said second attachment site via at least one non-peptide covalent bond. 
     
     
         35 . The composition of  claim 34 , wherein said first attachment site comprises an amino group of a lysine and said second attachment site comprises a sulfhydryl group of a cysteine. 
     
     
         36 . The composition of  claim 33 , wherein said core particle is a VLP of RNA-bacteriophage Qβ comprising one or more recombinant proteins consisting of the amino acid sequence as set forth in SEQ ID NO:1. 
     
     
         37 . The composition of  claim 36 , wherein said first attachment site is linked to said second attachment site via at least one non-peptide covalent bond. 
     
     
         38 . The composition of  claim 37 , wherein said first attachment site comprises an amino group of a lysine and said second attachment site comprises a sulfhydryl group of a cysteine. 
     
     
         39 . The composition of  claim 38  further comprising a hetero-bifunctional cross-linker, wherein said heterobifunctional cross-linker is SMPH. 
     
     
         40 . The composition of  claim 39 , wherein said fusion protein comprises the amino acid sequence as set forth in SEQ ID NO: 57.